The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial.
 
Christine Desmedt
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst)
Expert Testimony - Lilly (Inst)
 
Signe Borgquist
No Relationships to Disclose
 
Laura Garcia-Estevez
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; MSD Oncology
Research Funding - Roche/Genentech (Inst)
 
Miguel Martin
Stock and Other Ownership Interests - Pfizer
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - AstraZeneca; Novartis; Roche
 
Stephen Johnston
Honoraria - AstraZeneca; Lilly; Pfizer
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst)
Expert Testimony - Novartis
 
Fatima Cardoso
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline; IQvia; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva; touchIME
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Hakan Harputluoglu
No Relationships to Disclose
 
Hung Khong
Stock and Other Ownership Interests - agenus; MiNK Therapeutics; TG Therapeutics; Tiziana Life Sciences
Consulting or Advisory Role - Celcuity; Lilly
 
Belén San Antonio
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Maria Munoz
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Honoraria - AstraZeneca (I); BMS Norway (I); Gilead Sciences (I); Janssen (I); Lilly (I); MSD Oncology (I); Pfizer (I)
Consulting or Advisory Role - Accord Research (I); AstraZeneca (I); Janssen (I); MSD (I)
Research Funding - AstraZeneca (I); Roche (I)
 
Ran Wei
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics